Deltamethrin inhibits osteoclast differentiation via regulation of heme oxygenase-1 and NFATc1

Toxicology in Vitro

Volumn 26, Issue 6, 2012, Pages 817-822

  Sakamoto, Hiroshi ^a   Sakai, Eiko ^a   Fumimoto, Reiko ^a   Yamaguchi, Yu ^a   Fukuma, Yutaka ^a   Nishishita, Kazuhisa ^a   Okamoto, Kuniaki ^a   Tsukuba, Takayuki ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Deltamethrin; Heme oxygenase 1; NFATc1; Osteoclasts

Indexed keywords

CATHEPSIN K; DELTAMETHRIN; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NFATC1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; REGULATOR PROTEIN; SRC PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE METABOLISM; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; HEME OXYGENASE-1; INSECTICIDES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NFATC TRANSCRIPTION FACTORS; NITRILES; OSTEOCLASTS; PYRETHRINS; UP-REGULATION;

MURINAE;

EID: 84863828097     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.05.005     Document Type: Article

References (35)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol. 2000, 192:4-13.
3. Darnay B.G., Ni J., Moore P.A., Aggarwal B.B. Activation of NF-kappa B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 1999, 274:7724-7731.
4. Delaisse J.M., Andersen T.L., Engsig M.T., Henriksen K., Troen T., Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 2003, 61:504-513.
5. Elford P.R., Felix R., Cecchini M., Trechsel U., Fleisch H. Murine osteoblastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture. Calcif. Tissue Int. 1987, 41:151-156.
6. Emara A.M., Draz E.I. Immunotoxicological study of one of the most common over-the-counter pyrethroid insecticide products in Egypt. Inhal. Toxicol. 2007, 19:997-1009.
7. Enan E., Matsumura F. Specific inhibition of calcineurin by type II synthetic pyrethroid insecticides. Biochem. Pharmacol. 1992, 43:1777-1784.
8. Enan E., Pinkerton K.E., Peake J., Matsumura F. Deltamethrin-induced thymus atrophy in male Balb/c/mice. Biochem. Pharmacol. 1996, 51:447-454.
9. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
10. Gurunathan S., Robson M., Freeman N., Buckley B., Roy A., Meyer R., Bukowski J., Lioy P.J. Accumulation of chlorpyrifos on residential surfaces and toys accessible to children. Environ. Health Perspect 1998, 106:9-16.
11. Ha H., Kwak H.B., Lee S.W., Jin H.M., Kim H.M., Kim H.H., Lee Z.H. Reactive oxygenspecies mediate RANK signaling in osteoclasts. Exp. Cell Res. 2004, 301(2):119-127.
12. Hotokezaka H., Sakai E., Kanaoka K., Saito K., Matsuo K., Kitaura H., Yoshida N., Nakayama K. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem. 2002, 277:47366-47372.
13. Hu J.P., Nishishita K., Sakai E., Yoshida H., Kato Y., Tsukuba T., Okamoto K. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur. J. Pharmacol. 2008, 580:70-79.
14. Kamiya T., Kobayashi Y., Kanaoka K., Nakashima T., Kato Y., Mizuno A., Sakai H. Fluorescence microscopic demonstration of cathepsin K activity as the major lysosomal cysteine proteinase in osteoclasts. J. Biochem. 1998, 123:752-759.
15. 2+ oscillations essential for osteoclastogenesis. J. Biol. Chem. 2010, 285:6913-6921.
16. Kiviranta R., Morko J., Unsitalo H., Aro H.T., Vuorio E., Rantakokko J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res. 2001, 16:1444-1452.
17. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
18. Lee J.H., Jin H., Shim H.E., Kim H.N., Ha H., Lee Z.H. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Mol. Pharmacol. 2010, 77:17-25.
19. Lee N.K., Choi Y.G., Baik J.Y., Han S.Y., Jeong D.W., Bae Y.S., Kim N., Lee S.Y. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005, 106:852-859.
20. Li H.Y., Wu S.Y., Shi N. Transcription factor Nrf2 activation by deltamethrin in PC12 cells: involvement of ROS. Toxicol. Lett. 2007, 171:87-98.
21. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 2000, 275:31155-31161.
22. Narahara S., Matsushima H., Sakai E., Fukuma Y., Nishishita K., Okamoto K., Tsukuba T. Genetic backgrounds and redox conditions influence morphological characteristics and cell differentiation of osteoclasts in mice. Cell Tissue Res. 2012, 348:81-94.
23. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
24. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., Moritz J.D., Schu P., von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95:13453-13458.
25. Sakai E., Shimada-Sugawara M., Nishishita K., Fukuma Y., Naito M., Okamoto K., Nakayama K., Tsukuba T. Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis. J. Cell Biochem. 2012, 113:486-498.
26. Soderlund D.M., Clark J.M., Sheets L.P., Mullin L.S., Piccirillo V.J., Sargent D., Stevens J.T., Weiner M.L. Mechanisms of pyrethroid neurotoxicity: implications for cumulative risk assessment. Toxicology 2002, 171:3-59.
27. Song I., Kim J.H., Kim K., Jin H.M., Youn B.U., Kim N. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett. 2009, 583:2435-2440.
28. Soriano P., Montgomery C., Geske R., Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991, 64:693-702.
29. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T., Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3:889-901.
30. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
31. Watanabe T., Kukita T., Kukita A., Wada N., Toh K., Nagata K., Nomiyama H., Iijima T. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J. Endocrinol. 2004, 180:193-201.
32. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95:3597-3602.
33. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 2001, 276:563-568.
34. Zhou Z., Han J.Y., Xi C.X., Xie J.X., Feng X., Wang C.Y., Mei L., Xiong W.C. HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J. Bone Miner. Res. 2008, 23:1084-1096.
35. Zwerina J., Tzima S., Hayer S., Redlich K., Hoffmann O., Hanslik-Schnabel B., Smolen J.S., Kollias G., Schett G. Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J. 2005, 19:2011-2013.